Cumberland Pharmaceu (CPIX) Stock Price, Quote & News

Company Profile

Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for hospital acute care, gastroenterology, and oncology in the United States and internationally. The company offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative oral solution for the treatment of constipation; Sancuso, an...

Industry: Drug Manufacturers - Specialty & Generic

Sector: Healthcare

Phone: 615 255 0068

Fax: 615 255 0094

Website: www.cumberlandpharma.com

Address:

1600 West End Avenue, Suite 1300, Nashville, United States

BioResearcher Dec. 13 at 4:37 PM

$CPIX This is why Ifetroban will be a BLOCK-BUSTER drug !!! This is how Ifetroban stops cancers from spreading to other parts of body: "When cancer cells enter the bloodstream, they form bonds with blood platelets, effectively creating a "shield" around the cancer cell that hides it from white blood cells and other agents of the immune system. Ifetroban stops those platelet bonds from forming, which allows the immune system to target and remove cancer cells before they spread to a new location." - U of Miss Researchers

1 · Reply

BioResearcher Dec. 13 at 4:29 PM

$CPIX @haha1978 can you post this link to the original article from Univ of Miss : (for some reason I failed to post that link) This article has very good info about this cancer study.

1 · Reply

haha1978 Dec. 13 at 2:38 PM

$CPIX ai analysis page 2

0 · Reply

haha1978 Dec. 13 at 2:37 PM

$CPIX ai analysis page 1

0 · Reply

BioResearcher Dec. 13 at 5:48 AM

$CPIX I apologize for non-stop posting today on this board, But this finding by the 2 Universities are just HUGE !!! I am too excited to stop posting today. lol Once investors finish connecting the dots, we will have a lift off to the Moon !

1 · Reply

BioResearcher Dec. 13 at 5:13 AM

$CPIX Since Management has not PR this great finding yet. and CPIX is a tiny unknown company, Almost no investors have heard or know about this finding, They don't even know there is a link between this great finding and CPIX !!! They have not been able to connect the dots. One PR away from double digits here.

0 · Reply

BioResearcher Dec. 13 at 5:06 AM

$CPIX EXACTLY ! Ifetroban is owned by CPIX world wide rights. The beauty of this finding is it is INDEPENDENT of CPIX' influence; meaning: it is NOT pump and dump news. The study is funded by US Government. Not one, but TWO famous Universities researchers conducted this study for more than 5 years ago. University of Indiana & University of Miss.

1 · Reply

haha1978 Dec. 13 at 4:00 AM

$CPIX i was wrong they have the wirld rights for ifetroban. It could have been a collaboration with Vanderbilt since they discovered it in 2019. https://investor.cumberlandpharma.com/news-releases/news-release-details/cumberland-pharmaceuticals-announces-new-product-addition

0 · Reply

BioResearcher Dec. 13 at 12:06 AM

$CPIX This study started more than 5 years ago, they finally have the result recently. Here is the disclosure shows CPIX has no financial connection to this study, the study is totally independent: Note: CPI211 is now renamed: Ifetroban

1 · Reply

BioResearcher Dec. 12 at 11:44 PM

$CPIX This is very good news for cancer patients, especially the 3 most deadly cancers: breast, lung and pancreatic cancers. I love this description: :-) "(Ifetroban) would take the teeth out of aggressive diseases such as breast, lung and pancreatic cancers."

0 · Reply

CALDOLOR® (IBUPROFEN) INJECTION CMS ISSUED J-CODE NOW ASSOCIATED WITH REIMBURSEMENT PRICE SUPPORTING NON-OPIOID PAIN MANAGEMENT

Nov 4, 2025, 6:06 PM EST - 5 weeks ago

Cumberland Pharmaceuticals Inc. (CPIX) Q3 2025 Earnings Call Transcript

Nov 4, 2025, 5:00 PM EST - 5 weeks ago

CUMBERLAND PHARMACEUTICALS REPORTS 12% YEAR-TO-DATE REVENUE GROWTH

Oct 28, 2025, 4:05 PM EDT - 6 weeks ago

CUMBERLAND PHARMACEUTICALS TO ANNOUNCE Q3 2025 FINANCIAL RESULTS & COMPANY UPDATE

Oct 20, 2025, 9:05 AM EDT - 7 weeks ago

CUMBERLAND PHAMACEUTICALS ANNOUNCES THE ADDITION OF AN ESTABLISHED FDA APPROVED PRODUCT TO ITS COMMERCIAL PORTFOLIO

RDHL

Oct 20, 2025, 9:00 AM EDT - 7 weeks ago

RedHill's Talicia® Secures $4 Million Strategic Investment and U.S. Co-Commercialization Partnership Deal

Oct 13, 2025, 9:05 AM EDT - 2 months ago

CUMBERLAND PHARMACEUTICALS' VIBATIV® ADDED TO NATIONAL GROUP PURCHASING AGREEMENT WITH PREMIER, INC.

Oct 1, 2025, 9:05 AM EDT - 2 months ago

CUMBERLAND PHARMACEUTICALS ANNOUNCES PRODUCT APPROVAL IN MEXICO

Sep 29, 2025, 9:05 AM EDT - 2 months ago

TABUK LAUNCHES VIBATIV® FDA-APPROVED ANTIBIOTIC WITH LIFE-SAVING POTENTIAL IN SAUDI ARABIA

Aug 6, 2025, 3:48 PM EDT - 4 months ago

Cumberland (CPIX) Q2 Revenue Up 10%

Aug 6, 2025, 1:52 AM EDT - 4 months ago

Cumberland Pharmaceuticals Inc. (CPIX) Q2 2025 Earnings Call Transcript

Aug 5, 2025, 4:05 PM EDT - 4 months ago

Cumberland Pharmaceuticals Reports 23% Revenue Growth Year-to-Date

Aug 4, 2025, 9:05 AM EDT - 4 months ago

CUMBERLAND PHARMACEUTICALS RECEIVES VIZIENT CONTRACT FOR NEW VIBATIV® 4-VIAL STARTER PAK

Jul 29, 2025, 4:05 PM EDT - 4 months ago

CUMBERLAND PHARMACEUTICALS TO ANNOUNCE Q2 2025 FINANCIAL RESULTS & COMPANY UPDATE

Jun 23, 2025, 9:05 AM EDT - 6 months ago

Cumberland Pharmaceuticals Shares Phase 2 FIGHT DMD Trial Results at the Parent Project Muscular Dystrophy Annual Conference

May 27, 2025, 4:05 PM EDT - 7 months ago

NEW STUDY FINDS CALDOLOR® SAFE AND EFFECTIVE FOR OPIOID-SPARING PAIN MANAGEMENT IN OLDER ADULTS

May 13, 2025, 4:05 PM EDT - 7 months ago

CUMBERLAND PHARMACEUTICALS PARTNERS WITH QUREIGHT TO ADVANCE INNOVATIVE IDIOPATHIC PULMONARY FIBROSIS TREATMENT RESEARCH

May 10, 2025, 4:23 AM EDT - 7 months ago

Cumberland Pharmaceuticals, Inc. (CPIX) Q1 2025 Earnings Call Transcript

May 6, 2025, 4:05 PM EDT - 7 months ago

Cumberland Pharmaceuticals Reports 38% Revenue Growth in Q1 2025

Apr 29, 2025, 4:05 PM EDT - 8 months ago

CUMBERLAND PHARMACEUTICALS TO ANNOUNCE Q1 2025 FINANCIAL RESULTS & COMPANY UPDATE

Mar 19, 2025, 4:05 PM EDT - 9 months ago

FIGHT DMD Trial Results Selected for Late-Breaking Presentation at MDA Clinical & Scientific Conference

Mar 4, 2025, 7:14 PM EST - 10 months ago

Cumberland Pharmaceuticals Inc. (CPIX) Q4 2024 Earnings Call Transcript

Mar 4, 2025, 4:05 PM EST - 10 months ago

Cumberland Pharmaceuticals Reports 11.6% Fourth Quarter 2024 Revenue Growth

Feb 25, 2025, 4:05 PM EST - 10 months ago

CUMBERLAND PHARMACEUTICALS TO ANNOUNCE ANNUAL 2024 FINANCIAL RESULTS

Feb 18, 2025, 7:30 AM EST - 10 months ago

VIBATIV® RECEIVES MARKETING APPROVAL IN CHINA

Feb 4, 2025, 1:31 PM EST - 11 months ago

Cumberland Pharmaceuticals' Duchenne Candidate Shows Improved Heart Function In Patients With Associated Heart Disease

Feb 4, 2025, 7:30 AM EST - 11 months ago

Cumberland Pharmaceuticals Announces Breakthrough Results from the Phase 2 FIGHT DMD Trial in Duchenne Muscular Dystrophy Heart Disease

Dec 10, 2024, 12:08 PM EST - 1 year ago

Why Is Cumberland Pharmaceuticals Stock Trading Over 100% on Tuesday?

Dec 9, 2024, 4:05 PM EST - 1 year ago

FDA APPROVES ACETADOTE® sNDA

Nov 9, 2024, 1:17 PM EST - 1 year ago

Cumberland Pharmaceuticals Inc. (CPIX) Q3 2024 Earnings Call Transcript

Nov 7, 2024, 4:05 PM EST - 1 year ago

Cumberland Pharmaceuticals Reports Third Quarter 2024 Financial Results and Company Update

Nov 6, 2024, 5:21 PM EST - 1 year ago

CUMBERLAND PHARMACEUTICALS RECEIVES FDA ORPHAN DRUG AND RARE PEDIATRIC DISEASE DESIGNATIONS FOR NEW TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY

Nov 5, 2024, 4:05 PM EST - 1 year ago

New Study Compares Caldolor® (ibuprofen injection) to ketorolac

Oct 31, 2024, 4:05 PM EDT - 1 year ago

CUMBERLAND PHARMACEUTICALS TO ANNOUNCE THIRD QUARTER 2024 FINANCIAL RESULTS

Aug 11, 2024, 12:47 PM EDT - 1 year ago

Cumberland Pharmaceuticals Inc. (CPIX) Q2 2024 Earnings Call Transcript

Aug 6, 2024, 4:05 PM EDT - 1 year ago

Cumberland Pharmaceuticals Reports 16% Sequential Revenue Growth in Second Quarter 2024

Jul 30, 2024, 4:05 PM EDT - 1 year ago

CUMBERLAND PHARMACEUTICALS TO ANNOUNCE SECOND QUARTER 2024 FINANCIAL RESULTS

May 11, 2024, 11:51 PM EDT - 1 year ago

Cumberland Pharmaceuticals Inc. (CPIX) Q1 2024 Earnings Call Transcript

May 7, 2024, 4:05 PM EDT - 1 year ago

Cumberland Pharmaceuticals Reports First Quarter 2024 Financial Results & Company Update

Apr 30, 2024, 4:05 PM EDT - 1 year ago

CUMBERLAND PHARMACEUTICALS TO ANNOUNCE FIRST QUARTER 2024 FINANCIAL RESULTS

Apr 2, 2024, 4:05 PM EDT - 1 year ago

NEW REPORT SUPPORTS USE OF CALDOLOR® AS A STANDARD OF CARE ACROSS PATIENT POPULATIONS

Mar 5, 2024, 10:06 PM EST - 1 year ago

Cumberland Pharmaceuticals Inc. (CPIX) Q4 2023 Earnings Call Transcript

Mar 5, 2024, 4:05 PM EST - 1 year ago

Cumberland Pharmaceuticals Reports Annual 2023 Financial Results

Feb 27, 2024, 4:05 PM EST - 1 year ago

CUMBERLAND PHARMACEUTICALS TO ANNOUNCE ANNUAL 2023 FINANCIAL RESULTS

Nov 11, 2023, 8:17 AM EST - 2 years ago

Cumberland Pharmaceuticals Inc. (CPIX) Q3 2023 Earnings Call Transcript

Nov 7, 2023, 4:05 PM EST - 2 years ago

Cumberland Pharmaceuticals Reports Third Quarter 2023 Financial Results

Oct 31, 2023, 4:05 PM EDT - 2 years ago

CUMBERLAND PHARMACEUTICALS TO ANNOUNCE THIRD QUARTER 2023 FINANCIAL RESULTS

Oct 10, 2023, 4:05 PM EDT - 2 years ago

NEW VIBATV® PEDIATRIC PUBLICATION HIGHLIGHTS ITS SAFETY IN PATIENTS 2 TO 17 YEARS OF AGE

Aug 12, 2023, 4:21 AM EDT - 2 years ago

Cumberland Pharmaceuticals Inc. (CPIX) Q2 2023 Earnings Call Transcript

Aug 8, 2023, 4:05 PM EDT - 2 years ago

Cumberland Pharmaceuticals Reports Revenue and Earnings Growth Second Quarter 2023

BioResearcher Dec. 13 at 4:37 PM

1 · Reply

BioResearcher Dec. 13 at 4:29 PM

$CPIX @haha1978 can you post this link to the original article from Univ of Miss : (for some reason I failed to post that link) This article has very good info about this cancer study.

1 · Reply

haha1978 Dec. 13 at 2:38 PM

$CPIX ai analysis page 2

0 · Reply

haha1978 Dec. 13 at 2:37 PM

$CPIX ai analysis page 1

0 · Reply

BioResearcher Dec. 13 at 5:48 AM

1 · Reply

BioResearcher Dec. 13 at 5:13 AM

0 · Reply

BioResearcher Dec. 13 at 5:06 AM

1 · Reply

haha1978 Dec. 13 at 4:00 AM

0 · Reply

BioResearcher Dec. 13 at 12:06 AM

1 · Reply

BioResearcher Dec. 12 at 11:44 PM

0 · Reply

BioResearcher Dec. 12 at 11:31 PM

$CPIX Since Ifetroban is a repurposed drug to test on cancer metasis. Big Pham would love it because the remaining development time is significant shorter:

0 · Reply

BioResearcher Dec. 12 at 11:25 PM

$CPIX My concern is since this study is not sponsored or funded by CPIX, I am not sure if Management has the right to PR on this finding.

1 · Reply

BioResearcher Dec. 12 at 11:23 PM

$CPIX Exactly, my friend ! A drug that can stop the deadly cancers from spreading will have revenue of$ 4 - $ 5 $BILLION at least. Now, don't you think Big Pharm wants a drug like that in their pipeline ? That is why I believe BO is just around the corner. Keep in mind that the study is not sponsored by CPIX, The result is real and published by a well-known medical journal.

1 · Reply

haha1978 Dec. 12 at 11:10 PM

$CPIX this makes CPIX much more valuable if that p2 study works on humand due 4/2026. Surprised management is silent. There is so much behind the scenes they have like 5 or 6 p2 studies pending on ifetroban for next year. Hoping forva pop at somepoint.

0 · Reply

haha1978 Dec. 12 at 11:07 PM

$CPIX Bevacizumab a cancer metasis approved drug that starves cancer cells by preventing new blood vessels has a market size of 9 to 10 billion. These markets are much larger.

0 · Reply

BioResearcher Dec. 12 at 10:56 PM

$CPIX And this is another University is testing Ifetroban on Colorectal Cancer:

0 · Reply

BioResearcher Dec. 12 at 10:53 PM

$CPIX This is another trial by another University: Vanderbilt University. It focus on solid tumors (I believe BP will buyout CPIX soon)

0 · Reply

haha1978 Dec. 12 at 10:53 PM

$CPIX zebra fish cancer models. https://www.researchgate.net/publication/397577081_Targeting_platelet-tumor_cell_interactions_via_thromboxane_A2-prostanoid_receptor_blockade_to_reduce_metastasis_in_triple_negative_breast_cancer

0 · Reply

haha1978 Dec. 12 at 10:41 PM

$CPIX looks like its a p2 study with completition happening by April 2026. https://trial.medpath.com/clinical-trial/1cfc694db06d3f6d/nct03694249-pilot-trial-ifetroban-malignant-solid-tumors

0 · Reply

haha1978 Dec. 12 at 10:36 PM

$CPIX this has been ongoing for 6 years. Looks like a p1/p2 study results could be pending announcement. https://news.vumc.org/2019/07/08/clinical-study-prevent-cancer-metastasis/#:~:text=Cook%20and%20her%20colleagues%20found,at%20Vanderbilt%20University%20Medical%20Center.

0 · Reply

BioResearcher Dec. 12 at 10:16 PM

$CPIX In layman's terms, here is how Ifetroban can stop breast cancer from spreading:

0 · Reply

BioResearcher Dec. 12 at 9:55 PM

$CPIX Big pharma can just buy this drug then run a Phase 3 registration trial to confirm the efficacy. This is a high unmet need treatment, this is great news for cancer patients. because it has been proven safe and it is just an "add-on" treatment:

0 · Reply

Market Cap	37.84M
Revenue (ttm)	37.87M
Net Income (ttm)	-6.48M
EPS (ttm)	N/A
PE Ratio	31.13
Forward PE	N/A
Profit Margin	-17.11%
Debt to Equity Ratio	0.20

Volume	102,600
Avg Vol	66,262
Day's Range	N/A - N/A
Shares Out	14.96M
Stochastic %K	66%
Beta	-0.45
Analysts	Strong Buy
Price Target	$8.50